Advertisement

Serous Effusion Cytology

  • Qing Kay Li
Chapter
Part of the Atlas of Anatomic Pathology book series (AAP)

Abstract

Cytological evaluation of serous fluids plays an important role in the diagnosis and clinical management of patients. The etiology of pathological accumulation of serous fluids is broad, including both benign diseases, such as inflammation and infection, and malignant conditions, such as mesothelioma and metastatic carcinomas. Serous cavities are common sites of involvement by many metastatic tumors. The diagnosis of metastatic tumors is usually straightforward because most patients have a known malignant history, but challenges arise in difficult cases, such as in patients without a known malignant history, or in distinguishing a mesothelioma from an adenocarcinoma. Furthermore, the separation of reactive mesothelial cells from malignant mesothelioma can be difficult, usually requiring a panel of immunomarkers. Immunomarkers are also necessary for the identification of the primary site of a metastasis. This chapter summarizes current knowledge and guidelines regarding fluid cytology, key features of both benign and malignant lesions, differential diagnosis of a variety of benign and malignant effusions, and state-of-the-art ancillary tests using serous fluid specimens.

Keywords

Serous effusion cytology Pleural effusion Ascites Reactive mesothelial cells Benign and malignant effusions Mesothelioma Metastatic carcinoma 

Notes

Acknowledgment

The author sincerely thanks Dr. Yurong Y. Wheeler from the Department of Pathology at East Tennessee State University for her editorial help with the chapter.

References

  1. 1.
    Galateau-Salle F, Churg A, Roggli V, Travis WD, World Health Organization Committee for Tumors of the Pleura. The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification. J Thorac Oncol. 2016;11:142–54.CrossRefPubMedGoogle Scholar
  2. 2.
    Li QK, Chhieng DC. Rare metastatic tumors of non-epithelial origin. In: Michael C, Chhieng D, Bedrossian C, editors. Cytohistology of the serous membranes. Cambridge: Cambridge University Press; 2015. p. 195–213.Google Scholar
  3. 3.
    Cibas ES. Pleural, pericardial, and peritoneal fluids. In: Cibas ES, Ducatman BS, editors. Cytology: diagnostic principles and clinical correlates. 4th ed. Philadelphia: Saunders/Elsevier; 2014. p. 127–54.Google Scholar
  4. 4.
    Chuwa EW, Khin LW, Chan WH, Ong HS, Wong WK. Prognostic significance of peritoneal lavage cytology in gastric cancer in Singapore. Gastric Cancer. 2005;8:228–37.CrossRefPubMedGoogle Scholar
  5. 5.
    Passot G, Mohkam K, Cotte E, Glehen O. Intra-operative peritoneal lavage for colorectal cancer. World J Gastroenterol. 2014;20:1935–9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Davidson W, Madan R, O’Neil M, Tawfik OW, Fan F. Utility of peritoneal washing cytology in staging and prognosis of ovarian and fallopian tube neoplasms: a 10–year retrospective analysis. Ann Diagn Pathol. 2016;22:54–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Cefis F, Forni A, Carinelli S, Cangini L. Significance of ascitic fluid and peritoneal washing cytology in ovarian tumor diagnosis. Tumori. 1978;64:77–88.CrossRefPubMedGoogle Scholar
  8. 8.
    Jacques SM, Selvaggi SM. Multiple peritoneal cytologies collected during laparotomy for gynecologic malignancy. Diagn Cytopathol. 1991;7:482–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Bintcliffe OJ, Lee GY, Rahman NM, Maskell NA. The management of benign non-infective pleural effusions. Eur Respir Rev. 2016;25:303–16.CrossRefPubMedGoogle Scholar
  10. 10.
    Butnor KJ. My approach to the diagnosis of mesothelial lesions. J Clin Pathol. 2006;59:564–74.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ferreiro L, Auarez-Antelo J, Valdes L. Pleural procedures in the management of malignant effusions. Ann Thorac Med. 2017;12:3–10.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Sahn SA. Pleural diseases related to metastatic malignancies. Eur Respir J. 1997;10:1907–13.CrossRefPubMedGoogle Scholar
  13. 13.
    Hjerpe A, Ascoli V, Bedrossian CW, Boon ME, Creaney J, Davidson B, et al. International Mesothelioma Interest Group; International Academy of Cytology. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: complementary statement from the International Mesothelioma Interest Group, Also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. Diagn Cytopathol. 2015;43:563–76.CrossRefPubMedGoogle Scholar
  14. 14.
    Fischer AH, Zhao C, Li QK, Gustafson KS, Eltoum IE, Tambouret R, et al. The cytologic criteria of malignancy. J Cell Biochem. 2010;110:795–811.CrossRefPubMedGoogle Scholar
  15. 15.
    Li QK, Bavikatty N, Michael CW. The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion. Semin Diagn Pathol. 2006;23:15–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Jing X, Li QK, Bedrossian U, Michael CW. Morphologic and immunocytochemical performances of effusion cell blocks prepared using 3 different methods. Am J Clin Pathol. 2013;139:177–82.CrossRefPubMedGoogle Scholar
  17. 17.
    Karkhanis VS, Josh JM. Pleural effusion: diagnosis, treatment, and management. Open Access Emerg Med. 2012;4:31–52.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Nance KV, Shermer RW, Askin FB. Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. Mod Pathol. 1991;4:320–4.PubMedGoogle Scholar
  19. 19.
    Motherby H, Nadjari B, Friegel P, Kohaus J, Ramp U, Bocking A. Diagnostic accuracy of effusion cytology. Diagn Cytopathol. 1999;20:350–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Swiderek J, Morcos S, Donthireddy V, Surapaneni R, Jackson-Thompson V, Schultz L, et al. Prospective study to determine the volume of pleural fluid required to diagnose malignancy. Chest. 2010;137:68–73.CrossRefPubMedGoogle Scholar
  21. 21.
    Wu H, Khosla R, Rohatgi PK, Chauhan SS, Paal E, Chen W. The minimum volume of pleural fluid required to diagnose malignant pleural effusion: a retrospective study. Lung India. 2017;34:34–7.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Garcia LW, Ducatman BS, Wang HH. The value of multiple fluid specimens in the cytological diagnosis of malignancy. Mod Pathol. 1994;7:665–8.PubMedGoogle Scholar
  23. 23.
    Yu GH, Vergara N, Moore EM, King RL. Use of flow cytometry in the diagnosis of lymphoproliferative disorders in fluid specimens. Diagn Cytopathol. 2014;42:664–70.CrossRefPubMedGoogle Scholar
  24. 24.
    Chen Z, Wang DD, Peier A, Stone JF, Sandberg AA. FISH in the evaluation of pleural and ascitic fluids. Cancer Genet Cytogenet. 1995;84:116–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Mrvar-Brecko A, Sustar V, Jansa V, Stukelj R, Jansa R, Mujagić E, et al. Isolated microvesicles from peripheral blood and body fluids as observed by scanning electron microscope. Blood Cells Mol Dis. 2010;44:307–12.CrossRefPubMedGoogle Scholar
  26. 26.
    Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.CrossRefPubMedGoogle Scholar
  27. 27.
    Munfus-McCray D, Harada S, Adams C, Askin F, Clark D, Gabrielson E, Li QK. EGFR and KRAS mutations in metastatic lung adenocarcinomas. Hum Pathol. 2011;42:1447–53.CrossRefPubMedGoogle Scholar
  28. 28.
    Munfus-McCray D, Cui M, Zhang Z, Gabrielson E, Askin F, Li QK. Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect. Hum Pathol. 2013;44:1286–92.CrossRefPubMedGoogle Scholar
  29. 29.
    Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S. Challenges and controversies in the diagnosis of mesothelioma: part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol. 2013;66:847–53.CrossRefPubMedGoogle Scholar
  31. 31.
    Oba Y, Abu-Salah T. The prevalence and diagnostic significance of eosinophilic pleural effusions: a meta-analysis and systematic review. Respiration. 2012;83:198–208.CrossRefPubMedGoogle Scholar
  32. 32.
    Johnston WW. The malignant pleural effusion: a review of cytopathologic diagnosis of 584 specimens from 472 consecutive patients. Cancer. 1985;56:905–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Light RW. Primary effusions related to metastatic malignancies. In: Light RW, editor. Pleural diseases. 4th ed. Philadelphia: Lea & Febiger; 2001. p. 108–34.Google Scholar
  34. 34.
    Ammari ZA, Mollberg NM, Abdelhady K, Mansueto MD, Massad MG. Diagnosis and management of primary effusion lymphoma in the immunocompetent and immunocompromised hosts. Thorac Cardiovasc Surg. 2013;61:343–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Cigognetti M, Lonardi S, Fisogni S, Balzarini P, Pellegrini V, Tironi A, et al. BAP1 (BRCA1–associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015;28:1043–57.CrossRefGoogle Scholar
  36. 36.
    Longatto-Filho A, Bisi H, Bortolan J, Granja NV, Lombardo V. Cytologic diagnosis of metastatic sarcoma in effusions. Acta Cytol. 2003;47:317–8.PubMedGoogle Scholar
  37. 37.
    Abadi MA, Zakowski MF. Cytologic features of sarcoma in fluids. Cancer Cytopathol. 1998;84:71–6.CrossRefGoogle Scholar
  38. 38.
    Assoun S, Brosseau S, Steinmetz C, Gounant V, Zalcman G. Bevacizumab in advanced lung cancer: state of the art. Future Oncol. 2017;13(28):2515–35.  https://doi.org/10.2217/fon-2017-0302.CrossRefPubMedGoogle Scholar
  39. 39.
    Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol. 1983;23:175–80.CrossRefPubMedGoogle Scholar
  40. 40.
    Epstein JI, Egevad L, Humphrey PA, Montironi R, Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38:e6–19.CrossRefPubMedGoogle Scholar
  41. 41.
    Lilo MT, Allison D, Wang Y, Ao MH, Gabrielson E, Geddes S, et al. Expression of P40 and P63 in lung cancers using fine needle aspiration (FNA) cases. Understanding clinical pitfalls and limitations. J Am Soc Cytopathol. 2016;5:123–32.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Gurda GT, Zhang L, Wang Y, Chen L, Geddes S, Cho WC, et al. Utility of five commonly used immunohistochemical markers TTF-1, napsin A, CK7, P63 and CK5/6 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung. A retrospective study of 246 fine needle aspiration cases. Clin Transl Med. 2015;4:16.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Dong A, Lu Y, Lu B. Genomic/epigenomic alterations in ovarian carcinoma: translational insight into clinical practice. J Cancer. 2016;7:1441–51.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Lin SF, Gerry E, Shih IM. Tubal origin of ovarian cancer—the double-edged sword of haemoglobin. J Pathol. 2017;242:3–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Skala SL, Arps DP, Zhao L, Cha KB, Wang M, Harms PW, et al. Comprehensive histopathologic comparison of epidermotropic/dermal metastatic melanoma and primary nodular melanoma. Histopathology. 2018;72(3):472–80.  https://doi.org/10.1111/his.13384.CrossRefPubMedGoogle Scholar
  46. 46.
    Moran CA, Suster S, Koss MN. The spectrum of histologic growth patterns in benign and malignant fibrous tumors of the pleura. Semin Diagn Pathol. 1992;9:169–80.PubMedGoogle Scholar
  47. 47.
    Boucher LD, Swanson PE, Stanley MW, Silverman JF, Raab SS, Geisinger KR. Cytology of angiosarcoma. Findings in fourteen fine-needle aspiration biopsy specimens and on pleural fluid specimen. Am J Clin Pathol. 2000;114:210–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Zhang PJ, Livolsi VA, Brooks JJ. Malignant epithelioid vascular tumors of the pleura: report of a series and literature review. Hum Pathol. 2000;31:29–34.CrossRefPubMedGoogle Scholar
  49. 49.
    Crotty EJ, McAdams HP, Erasmus JJ, Sporn TA, Roggli VL. Epithelioid hemangioendothelioma of the pleura: clinical and radiologic features. AJR Am J Roentgenol. 2000;175:1545–9.CrossRefPubMedGoogle Scholar
  50. 50.
    Cagle PT, Hicks MJ, Haque A. Desmoplastic small round cell tumor of the pleura: report of two new cases and review of the literature. Histopathology. 2002;41:164–8.Google Scholar
  51. 51.
    Gaertner E, Zeren EH, Fleming MV, Colby TV, Travis WD. Biphasic synovial sarcomas arising in the pleural cavity: a clinicopathologic study of five cases. Am J Surg Pathol. 1996;20:36–45.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pathology and OncologyThe Johns Hopkins Medical InstitutionsBaltimoreUSA

Personalised recommendations